In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma

BACKGROUND: Immune checkpoint inhibitors (ICIs) have significantly improved the outcome in metastatic cutaneous melanoma (CM). However, therapy response is limited to subgroups of patients and clinically useful predictive biomarkers are lacking. METHODS: To discover treatment-related systemic change...

Descripción completa

Detalles Bibliográficos
Autores principales: Babačić, Haris, Lehtiö, Janne, Pico de Coaña, Yago, Pernemalm, Maria, Eriksson, Hanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253007/
https://www.ncbi.nlm.nih.gov/pubmed/32457125
http://dx.doi.org/10.1136/jitc-2019-000204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253007/
https://www.ncbi.nlm.nih.gov/pubmed/32457125
http://dx.doi.org/10.1136/jitc-2019-000204

Ejemplares similares